Unicycive Therapeutics, Inc. (UNCY) Misses Q1 EPS by 82c

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q1 EPS of ($0.97), $0.82 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $675 thousand.

For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.

You May Also Be Interested In

• Goldman Regional Director in US Adjusts List of Top Names
• Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
• Constellation Brands (STZ) Tops Q1 EPS by 18c